Today: 28 June 2026
Browse Category

Biotechnology 23 February 2026 - 4 May 2026

Cabaletta Bio Stock Jumps: Inside the $150 Million Bet on CABA’s Cell Therapy

Cabaletta Bio Stock Jumps: Inside the $150 Million Bet on CABA’s Cell Therapy

Cabaletta Bio shares surged 32% after the company reported early results from its cell-therapy trial and priced a $150 million stock offering with participation from Eli Lilly and others. Two of four pemphigus vulgaris patients showed clinical activity with rese-cel, its experimental CAR-T therapy. The company expects to fund operations into mid-2027. New data will be presented at the ASGCT meeting on May 14.
4 May 2026
····
Mirum Stock Jumps After Volixibat Trial Win Puts First PSC Itch Drug Within Reach

Mirum Stock Jumps After Volixibat Trial Win Puts First PSC Itch Drug Within Reach

Mirum Pharmaceuticals said its drug volixibat met the main goal in a 158-patient Phase 2b trial for primary sclerosing cholangitis, reducing itch scores more than placebo. Shares rose about 9% after the announcement. The company plans a pre-NDA meeting with the FDA this summer and aims to file for U.S. approval in the second half of 2026. No FDA-approved therapies currently exist for this rare liver disease.
4 May 2026
··
Celcuity Stock Jumps 16% as Gedatolisib Breast-Cancer Data Raise FDA Stakes

Celcuity Stock Jumps 16% as Gedatolisib Breast-Cancer Data Raise FDA Stakes

Celcuity Inc. shares rose nearly 16% Monday after reporting its breast cancer drug gedatolisib met the main goal in a late-stage trial for patients with PIK3CA-mutant tumors. The company plans to submit the new data to the FDA as a supplemental application. Celcuity traded at $145.54, up $19.89, with a market value near $6.9 billion. A July 17 FDA decision on gedatolisib for a related use remains pending.
4 May 2026
···
Why iSpecimen Stock Whipsawed After Its 1-for-40 Reverse Split

Why iSpecimen Stock Whipsawed After Its 1-for-40 Reverse Split

iSpecimen Inc. shares fell 8.2% to $4.80 Friday after volatile trading, following a 1-for-40 reverse stock split aimed at meeting Nasdaq’s minimum bid price. The split reduced outstanding shares from 52.6 million to about 1.3 million. Nasdaq has given the company until May 18 to regain compliance. The annual meeting is set for May 8 after previous adjournments due to lack of quorum.
1 May 2026
··
Alexandria Real Estate Stock Slides as Lab-Leasing Weakness Overshadows Q1 Profit Jump

Alexandria Real Estate Stock Slides as Lab-Leasing Weakness Overshadows Q1 Profit Jump

Alexandria Real Estate Equities shares fell 9% Tuesday after first-quarter adjusted FFO dropped to $1.73 a share from $2.30 a year earlier and revenue declined to $671 million. The company lowered its 2026 occupancy and rental-rate assumptions but kept its adjusted FFO midpoint at $6.40. Net income rose to $358.9 million on a debt-repurchase gain. BNP Paribas Exane cut its price target to $44.
28 April 2026
····
Baiya International’s $1 Million BNB Bet Sends BIYA Stock Sharply Higher

Baiya International’s $1 Million BNB Bet Sends BIYA Stock Sharply Higher

Baiya International Group said Binance Coin (BNB) won 89.2% of a public vote and will be the first core digital asset in its new “Cryptocurrency Ark Plan.” BIYA shares surged 82% to $1.42 on Nasdaq, with trading volume near 184 million. The company plans an initial $1 million BNB purchase and will use trading gains for share buybacks. Recent filings indicate possible equity dilution as Baiya moves into crypto trading.
28 April 2026
··
Intellia Therapeutics Stock Jumps After Hours Ahead of First Phase 3 In Vivo CRISPR Readout

Intellia Therapeutics Stock Jumps After Hours Ahead of First Phase 3 In Vivo CRISPR Readout

Intellia Therapeutics will release Phase 3 data Monday from its HAELO trial of lonvoguran ziclumeran, an in vivo CRISPR gene-editing therapy for hereditary angioedema. The study enrolled 80 patients, testing a single 50 mg infusion against placebo. Intellia shares rose 19.3% after hours Friday ahead of the announcement. The company ended 2025 with $605.1 million in cash and expects it to last into late 2027.
25 April 2026
···
Eli Lilly to Buy Kelonia for Up to $7 Billion as In Vivo CAR-T Gains Ground

Eli Lilly to Buy Kelonia for Up to $7 Billion as In Vivo CAR-T Gains Ground

Eli Lilly will acquire Boston-based Kelonia Therapeutics for up to $7 billion in cash, including $3.25 billion upfront, to expand into in vivo CAR-T cancer therapies. Kelonia’s KLN-1010, in Phase 1 for multiple myeloma, generates engineered T-cells inside the patient. The deal marks Lilly’s third Massachusetts biotech purchase in 2026. Kelonia had 62 employees and nearly ran out of cash before the offer.
21 April 2026
··
Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Definium Therapeutics shares rose to $22.68 after Stifel and Piper Sandler initiated coverage with Buy ratings, citing late-stage trials of DT120, an LSD-based tablet for anxiety and depression. The company will host an investor day April 22 in New York to discuss upcoming Phase 3 data. DT120 is in four pivotal studies, with top-line results expected through 2026. Johnson & Johnson and Compass Pathways are advancing rival clinic-based psychiatric drugs.
18 April 2026
··
Hims & Hers Stock Surges as FDA Reopens Peptide Rules, Shifting Focus Beyond GLP-1 Drama

Hims & Hers Stock Surges as FDA Reopens Peptide Rules, Shifting Focus Beyond GLP-1 Drama

Hims & Hers Health shares rose 14% to $24.29 after the FDA said it will review restrictions on several peptides, including BPC-157 and TB-500. The agency set a July advisory meeting and will remove some peptides from its safety-risk list within a week. Hims, which acquired a California peptide facility last year, reported $2.35 billion in 2025 revenue and 2.511 million subscribers.
15 April 2026
··
Soleno Therapeutics Pulls Europe Drug Filing After $2.9 Billion Neurocrine Deal

Soleno Therapeutics Pulls Europe Drug Filing After $2.9 Billion Neurocrine Deal

Soleno Therapeutics withdrew its European filing for VIOKAT on Tuesday, halting a regulatory review that was expected to conclude in 2026. The move came one day after Neurocrine Biosciences agreed to acquire Soleno for $2.9 billion in cash, or $53 a share. Vykat XR, Soleno’s only marketed product, generated $190.4 million in 2025 U.S. sales. Neurocrine said it has no immediate plans for a European launch.
7 April 2026
···
BioCryst (BCRX) stock price dips premarket as new navenibart HAE data lands; Cowen talk next

BioCryst (BCRX) stock price dips premarket as new navenibart HAE data lands; Cowen talk next

BioCryst Pharmaceuticals shares fell 2.9% to $8.50 premarket Monday after new clinical data on its hereditary angioedema drug pipeline. Interim results from the ALPHA-SOLAR study showed navenibart reduced mean monthly HAE attacks by 91% among 29 patients, with one discontinuation due to cancer. The company reaffirmed 2026 revenue guidance for ORLADEYO and expects a Phase 3 navenibart filing by late 2027.
2 March 2026
·
Eli Lilly stock snaps skid on orforglipron pill data as April FDA clock nears

Eli Lilly stock snaps skid on orforglipron pill data as April FDA clock nears

Eli Lilly shares rose 2.93% to $1,051.99 Friday, outperforming a falling market. Full results from a diabetes trial showed Lilly’s oral drug orforglipron caused more nausea and discontinuations than Novo Nordisk’s Rybelsus, but produced greater A1C and weight reduction. The 52-week study involved 1,698 patients. Novo plans to cut U.S. list prices for Ozempic and Wegovy by up to 50% starting in 2027.
28 February 2026
···
CRISPR Therapeutics stock whipsaws again as takeover talk resurfaces — here’s what to watch

CRISPR Therapeutics stock whipsaws again as takeover talk resurfaces — here’s what to watch

CRISPR Therapeutics shares fell 1.9% to $60.55 in premarket trading Friday after an 11.85% surge Thursday on renewed takeover speculation flagged by Betaville, The Fly reported. The company reported $116 million in 2025 Casgevy revenue and ended the year with $1.98 billion in cash. Management is set to appear at investor conferences starting March 2.
27 February 2026
···
Stoke Therapeutics stock swings premarket after Wolfe starts coverage with $40 target (STOK)

Stoke Therapeutics stock swings premarket after Wolfe starts coverage with $40 target (STOK)

Stoke Therapeutics shares dropped 1.2% to $35.80 in early premarket trading Tuesday, after a 5.7% gain the previous session. Wolfe Research began coverage with an “Outperform” rating and a $40 price target. Investors are watching for updates on the company’s Phase 3 Dravet syndrome trial with Biogen. About 21.6% of Stoke’s float is sold short, according to MarketBeat.
24 February 2026
···
Gossamer Bio stock tumbles again premarket as Phase 3 PAH miss rewrites the story

Gossamer Bio stock tumbles again premarket as Phase 3 PAH miss rewrites the story

Gossamer Bio shares traded near $0.42 in early premarket Tuesday after plunging about 80% when its main drug failed to meet the primary goal in a Phase 3 trial. The company said the study’s key endpoint improved by 13.3 meters but did not reach statistical significance. Analysts downgraded the stock and flagged risks around funding and regulatory timelines. Gossamer plans to meet the FDA and paused another study.
24 February 2026
···
Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod

Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod

Eli Lilly shares climbed nearly 5% late Monday after Novo Nordisk reported its obesity drug CagriSema underperformed Lilly’s Zepbound in a head-to-head trial. Novo’s U.S.-listed shares dropped over 16%. CagriSema showed 23% weight loss after 84 weeks, compared to 25.5% for Zepbound. The trial failed to prove CagriSema was not worse than tirzepatide on weight loss.
23 February 2026
····
1 2 3 4 5 … 19

Stock Market Today

  • Dodla Dairy Earnings Highlight Profit Boost from Unusual Items
    June 28, 2026, 12:01 AM EDT. Dodla Dairy Limited's latest earnings reveal a ₹246 million boost from unusual items, raising concerns about the sustainability of profit growth. Despite strong earnings per share growth over three years, the one-off nature of these gains suggests potential profit declines if such contributions do not recur. Analysts emphasize caution interpreting statutory profits as a true reflection of ongoing business performance. Investors should consider underlying risks flagged by market data and examine broader financial metrics such as return on equity and insider holdings. The mixed signals have kept the stock price largely unchanged, indicating market apprehension about earnings quality and future profitability.

Latest articles

Hecla Mining (NYSE:HL) sees stock rebound, volume jumps as silver prices in focus

Hecla Mining (NYSE:HL) sees stock rebound, volume jumps as silver prices in focus

28 June 2026
Hecla Mining surged 5.3 times its average trading volume Friday as index rebalancing drove 112.44 million shares traded, but the stock’s 2.6% weekly drop still beat silver and peer ETFs, signaling company-specific strength; investors now watch if Hecla can hold above $15.54 without rebalancing flows as macro risks loom.
Go toTop